{"id":"alz-801","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL5847740","moleculeType":null,"molecularWeight":"362.44"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by inhibiting the production of amyloid beta peptides, which are thought to contribute to the progression of Alzheimer's disease. By reducing the levels of these peptides, ALZ-801 aims to slow down the disease's progression.","oneSentence":"ALZ-801 is a dual A beta 42 and A beta 40 inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:35.879Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT04693520","phase":"PHASE2","title":"Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease","status":"COMPLETED","sponsor":"Alzheon Inc.","startDate":"2020-09-30","conditions":"Early Alzheimer's Disease","enrollment":84},{"nctId":"NCT04770220","phase":"PHASE3","title":"An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects","status":"COMPLETED","sponsor":"Alzheon Inc.","startDate":"2021-05-19","conditions":"Early Alzheimer's Disease","enrollment":325},{"nctId":"NCT06304883","phase":"PHASE3","title":"Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alzheon Inc.","startDate":"2024-04-02","conditions":"Early Alzheimer's Disease","enrollment":163},{"nctId":"NCT04585347","phase":"PHASE1","title":"Single Dose Study of ALZ-801 Prototype Tablets","status":"COMPLETED","sponsor":"Alzheon Inc.","startDate":"2015-09-16","conditions":"Alzheimer Disease","enrollment":12},{"nctId":"NCT04157712","phase":"PHASE1","title":"Multiple Ascending Dose Study of ALZ-801","status":"COMPLETED","sponsor":"Alzheon Inc.","startDate":"2015-09-26","conditions":"Alzheimer Disease","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ALZ-801","genericName":"ALZ-801","companyName":"Alzheon Inc.","companyId":"alzheon-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALZ-801 is a dual A beta 42 and A beta 40 inhibitor. Used for Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}